Dr. Tom Zwaenepoel, Reumatologie
0689.639.910 · rovalta.com · 27/09/2026
Dr. Tom Zwaenepoel, Reumatologie
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBODr. Tom Zwaenepoel, Reumatologie is a Private limited company incorporated in 2018. Its registered office is in Aalst.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0689.639.910
- Incorporation
- 31/01/2018
- Legal form
- Private limited company
- Registered office
- Mortelveld 9A
9320 Aalst · FlandreSee on map - Contributed capital
- 12 400,00 €
- Latest accounts
- 31/12/2025
Financials
Source · NBB, 8 filingsTrend over 8 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 111,9 k € | -44.5% | 201,4 k € | +50.8% | 133,6 k € | +5.5% | 126,6 k € | -8.2% | 138 k € |
| EBITDA | 110,3 k € | -44.8% | 199,8 k € | +52.4% | 131,2 k € | +5.9% | 123,8 k € | -8.4% | 135,2 k € |
| Operating result | 84,1 k € | -45.6% | 154,6 k € | +80.1% | 85,9 k € | +41.0% | 60,9 k € | -16.3% | 72,7 k € |
| Net result | 53,9 k € | -46.8% | 101,4 k € | +90.9% | 53,1 k € | +51.5% | 35,1 k € | -19.8% | 43,7 k € |
| Balance sheet | |||||||||
| Equity | 332,5 k € | +18.7% | 280,3 k € | +55.2% | 180,5 k € | +39.9% | 129 k € | +35.0% | 95,5 k € |
| Total assets | 890,3 k € | +3.7% | 858,8 k € | +4.1% | 825,1 k € | +3.2% | 799,4 k € | -10.5% | 893,3 k € |
| Cash | 24,4 k € | -16.4% | 29,2 k € | +244% | 8,5 k € | -75.0% | 34 k € | -49.0% | 66,8 k € |
| Debts | 556,1 k € | -3.9% | 578,5 k € | -10.2% | 644,6 k € | -3.8% | 670,3 k € | -16.0% | 797,8 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20251 active · 3 ended
Active mandates
| Director | Function | Mandate |
|---|---|---|
Tom Zwaenepoel | Manager |
Ended mandates
| Director | Function | Mandate |
|---|---|---|
TOM ZWAENEPOEL | Director | since 31/01/2018 |
TOM ZWAENEPOEL | Manager | since 31/01/2018 |
Tom Zwaenepoel | Director |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 30/06/2026 | 22/08/2025 | 27/06/2024 | 28/06/2023 | 25/08/2022 | 27/07/2021 |
| General meeting | 20/06/2026 | 20/06/2025 | 20/06/2024 | 20/06/2023 | 20/06/2022 | 21/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 8 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2025 | 20/06/2026 | 30/06/2026 | Dutch | |
| Micro model | 31/12/2024 | 20/06/2025 | 22/08/2025 | Dutch | |
| Micro model | 31/12/2023 | 20/06/2024 | 27/06/2024 | Dutch | |
| Micro model | 31/12/2022 | 20/06/2023 | 28/06/2023 | Dutch | |
| Micro model | 31/12/2021 | 20/06/2022 | 25/08/2022 | Dutch | |
| Micro model | 31/12/2020 | 21/06/2021 | 27/07/2021 | Dutch | |
| Micro model | 31/12/2019 | 20/06/2020 | 24/08/2020 | Dutch | |
| Micro model | 31/12/2018 | 20/06/2019 | 02/07/2019 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 250 k€ and 500 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active · 3 ended
Active mandates
| Director | Function | Mandate |
|---|---|---|
Tom Zwaenepoel | Manager |
Ended mandates
| Director | Function | Mandate |
|---|---|---|
TOM ZWAENEPOEL | Director | since 31/01/2018 |
TOM ZWAENEPOEL | Manager | since 31/01/2018 |
Tom Zwaenepoel | Director |
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 202553,9 k €↓
- 2024Annual accounts 2024101,4 k €↑
- 2023Annual accounts 202353,1 k €↑
- 2022Annual accounts 202235,1 k €↓
- 2021Annual accounts 202143,7 k €↑
- 2020Annual accounts 202020,6 k €↓
- 2019Annual accounts 201922,4 k €↑
- 2018Annual accounts 20182,8 k €
- 31/01/2018IncorporationPrivate limited company
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| Dr. Tom Zwaenepoel, ReumatologieCurrent | CBE, tracked since 27/09/2026 | CBE |
| DR. TOM ZWAENEPOEL | accounts 2021 → 2025 | Accounts 2025 · 2026-00235810 |
Annual accounts date a value by the financial year it appears in. The CBE dates a change to the day, but its history has only been kept since 27/09/2026.